EHMT2 and neoplasm: Our data showed that metastatic tumor samples had a significantly higher expression of EHMT2/G9a than primary or recurrent tumor samples, at both the mRNA (p = 0.0008) and the protein (p = 0.0005) levels (Fig. 1E, F).